Twist Bioscience stock
TWSTNASDAQTwist Bioscience Corporation, HealthcareISIN US90184D1000
46Score 46 out of 100, Weak
Price and trend
68 / 100
Price history
+258% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 41).
The price is 44% below its 52-week high. Largest decline in 8 years: 94% (January 2021 to May 2023).
Chart figures for advanced users
- SMA 50$150.57
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$92.89
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)41
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$25.45
- The lowest closing price of the last twelve months.
- Resistance$205.00
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Twist Bioscience Corporation belongs to the Biotechnology industry (United States) and, with a market value of $7.52B, is number 53 of 289 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $459.43M (up 22% year on year) and a loss of $130.2M.
- For fiscal 2027, analysts expect on average revenue of $548.62M (up 19.4%) and adjusted earnings per share of −$1.33.
Show more
- MEQIRI Score 46 out of 100 (Weak): rank 445 of 702 in Healthcare, median 53.
- Our model puts fair value at $62.71, with the price 82% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $581.91M, financial debt $94.99M (fiscal 2026).Stability 68
Weaknesses
- DilutionShare count up 30% since 2021.Capital allocation 18
- Loss-makingLoss of $130.2M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 84% a year over the last 12 months.Stability 68
Its standout strengths are momentum and growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 45 to 46.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
- high price swings
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $41.80 and expensive above $125.41 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $52.14, at 8.3% it would be $78.07.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue rose 22% on the prior year. Revenue has grown strongly since 2016, at around 70% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 52%, operating −30%, net −28%.
Debt & balance sheet
Fiscal 2026Debt is low; no interest coverage is reported.
Earnings
- Next earnings
- 29 Jan 2027in 77 days
- Last reported
- 12 Nov 2026EPS reported −$0.32 (expected −$0.39)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.33−1.4%
- Revenue
- $548.62M0.0%
- Earnings per share
- −$0.870.0%
- Revenue
- $645.84M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +8.6%Fiscal 2026 revenue guidance raised by $12 million at the midpoint to $456 million to $457 million, with gross margin above 52% expected.
“For fiscal '26, we are increasing our revenue guidance and now expect total revenue of $456 million to $457 million, up $12 million at the midpoint, representing growth of approximately 21% year-over-year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 9 insiders sold, $134.23M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Cho DennisSale
3 Nov 2026, See Remarks
- Shares
- 949
- Price
- $135.40
- Value
- $128,496
- Finn Patrick JohnSale
3 Nov 2026, President and COO
- Shares
- 2,565
- Price
- $135.40
- Value
- $347,306
- Leproust Emily M.Sale
3 Nov 2026, Chief Executive Officer
- Shares
- 4,573
- Price
- $135.40
- Value
- $619,193
Show 67 more
- Werner Robert F.Sale
3 Nov 2026, Chief Accounting Officer
- Shares
- 148
- Price
- $135.40
- Value
- $20,039
- Green PaulaSale
3 Nov 2026, SVP of Human Resources
- Shares
- 1,007
- Price
- $135.40
- Value
- $136,350
- Finn Patrick JohnSale
23 Oct 2026, President and COO
- Shares
- 2,245
- Price
- $134.59
- Value
- $302,152
- Laponis AdamSale
9 Oct 2026, Chief Financial Officer
- Shares
- 2,462
- Price
- $156.30
- Value
- $384,823
- Leproust Emily M.Sale
5 Oct 2026, Chief Executive Officer
- Shares
- 4,548
- Price
- $202.15
- Value
- $919,374
- Laponis AdamSale
2 Oct 2026, Chief Financial Officer
- Shares
- 8,057
- Price
- $188.88
- Value
- $1.52M
- Green PaulaSale
2 Oct 2026, SVP of Human Resources
- Shares
- 10,088
- Price
- $188.88
- Value
- $1.91M
- Finn Patrick JohnSale
2 Oct 2026, President and COO
- Shares
- 25,714
- Price
- $188.88
- Value
- $4.86M
- Leproust Emily M.Sale
2 Oct 2026, Chief Executive Officer
- Shares
- 45,736
- Price
- $188.88
- Value
- $8.64M
- Cho DennisSale
2 Oct 2026, See Remarks
- Shares
- 9,514
- Price
- $188.88
- Value
- $1.8M
- Werner Robert F.Sale
2 Oct 2026, Chief Accounting Officer
- Shares
- 1,482
- Price
- $188.88
- Value
- $279,926
- Leproust Emily M.Sale
1 Oct 2026, Chief Executive Officer
- Shares
- 655
- Price
- $200.00
- Value
- $131,000
- Leproust Emily M.Sale
24 Sept 2026, Chief Executive Officer
- Shares
- 5,203
- Price
- $177.38
- Value
- $922,907
- Cho DennisSale
21 Sept 2026, See Remarks
- Shares
- 348
- Price
- $165.49
- Value
- $57,591
- Green PaulaSale
21 Sept 2026, SVP of Human Resources
- Shares
- 294
- Price
- $165.49
- Value
- $48,654
- Leproust Emily M.Sale
21 Sept 2026, Chief Executive Officer
- Shares
- 1,687
- Price
- $165.49
- Value
- $279,183
- Leproust Emily M.Sale
17 Sept 2026, Chief Executive Officer
- Shares
- 356,546
- Price
- $157.99
- Value
- $56.33M
- Cho DennisSale
8 Sept 2026, See Remarks
- Shares
- 412
- Price
- $122.62
- Value
- $50,521
- Green PaulaSale
8 Sept 2026, SVP of Human Resources
- Shares
- 907
- Price
- $122.62
- Value
- $111,220
- Leproust Emily M.Sale
8 Sept 2026, Chief Executive Officer
- Shares
- 2,302
- Price
- $122.62
- Value
- $282,280
- Werner Robert F.Sale
8 Sept 2026, Chief Accounting Officer
- Shares
- 238
- Price
- $122.62
- Value
- $29,185
- Leproust Emily M.Sale
25 Aug 2026, Chief Executive Officer
- Shares
- 41,570
- Price
- $151.98
- Value
- $6.32M
- Werner Robert F.Sale
24 Aug 2026, Chief Accounting Officer
- Shares
- 854
- Price
- $140.77
- Value
- $120,220
- Cho DennisSale
21 Aug 2026, See Remarks
- Shares
- 1,598
- Price
- $139.07
- Value
- $222,227
- Finn Patrick JohnSale
21 Aug 2026, President and COO
- Shares
- 4,046
- Price
- $139.07
- Value
- $562,661
- Green PaulaSale
21 Aug 2026, SVP of Human Resources
- Shares
- 1,360
- Price
- $139.07
- Value
- $189,130
- Laponis AdamSale
21 Aug 2026, Chief Financial Officer
- Shares
- 1,965
- Price
- $139.07
- Value
- $273,265
- Leproust Emily M.Sale
21 Aug 2026, Chief Executive Officer
- Shares
- 6,639
- Price
- $139.07
- Value
- $923,259
- Werner Robert F.Sale
21 Aug 2026, Chief Accounting Officer
- Shares
- 669
- Price
- $139.07
- Value
- $93,035
- Cho DennisSale
19 Aug 2026, See Remarks
- Shares
- 14,205
- Price
- $129.75
- Value
- $1.84M
- Finn Patrick JohnSale
18 Aug 2026, President and COO
- Shares
- 78,355
- Price
- $117.64
- Value
- $9.22M
- Blake KatrynSale
12 Aug 2026, Board
- Shares
- 2,240
- Price
- $122.88
- Value
- $275,251
- Leproust Emily M.Sale
12 Aug 2026, Chief Executive Officer
- Shares
- 19,952
- Price
- $125.08
- Value
- $2.5M
- Leproust Emily M.Sale
10 Aug 2026, Chief Executive Officer
- Shares
- 113,318
- Price
- $125.16
- Value
- $14.18M
- Chess RobertSale
7 Aug 2026, Board
- Shares
- 18,417
- Price
- $110.89
- Value
- $2.04M
- Cho DennisSale
5 Aug 2026, See Remarks
- Shares
- 14,205
- Price
- $109.75
- Value
- $1.56M
- Finn Patrick JohnSale
3 Aug 2026, President and COO
- Shares
- 2,888
- Price
- $85.32
- Value
- $246,408
- Green PaulaSale
3 Aug 2026, SVP of Human Resources
- Shares
- 1,133
- Price
- $85.32
- Value
- $96,669
- Leproust Emily M.Sale
3 Aug 2026, Chief Executive Officer
- Shares
- 5,101
- Price
- $85.32
- Value
- $435,223
- Werner Robert F.Sale
3 Aug 2026, Chief Accounting Officer
- Shares
- 167
- Price
- $85.32
- Value
- $14,249
- Cho DennisSale
3 Aug 2026, See Remarks
- Shares
- 1,070
- Price
- $85.32
- Value
- $91,294
- Finn Patrick JohnSale
23 Jul 2026, President and COO
- Shares
- 2,238
- Price
- $93.89
- Value
- $210,133
- Laponis AdamSale
9 Jul 2026, Chief Financial Officer
- Shares
- 2,399
- Price
- $94.33
- Value
- $226,307
- Leproust Emily M.Sale
25 Jun 2026, Chief Executive Officer
- Shares
- 18,880
- Price
- $95.00
- Value
- $1.79M
- Cho DennisSale
24 Jun 2026, See Remarks
- Shares
- 14,205
- Price
- $89.75
- Value
- $1.27M
- Green PaulaSale
22 Jun 2026, SVP of Human Resources
- Shares
- 291
- Price
- $87.32
- Value
- $25,411
- Cho DennisSale
22 Jun 2026, See Remarks
- Shares
- 346
- Price
- $87.32
- Value
- $30,214
- Leproust Emily M.Sale
22 Jun 2026, Chief Executive Officer
- Shares
- 1,688
- Price
- $87.32
- Value
- $147,400
- Green PaulaSale
15 Jun 2026, SVP of Human Resources
- Shares
- 26,137
- Price
- $81.67
- Value
- $2.13M
- Cho DennisSale
8 Jun 2026, See Remarks
- Shares
- 402
- Price
- $69.84
- Value
- $28,077
- Green PaulaSale
8 Jun 2026, SVP of Human Resources
- Shares
- 884
- Price
- $69.84
- Value
- $61,742
- Leproust Emily M.Sale
8 Jun 2026, Chief Executive Officer
- Shares
- 2,265
- Price
- $69.84
- Value
- $158,197
- Werner Robert F.Sale
8 Jun 2026, Chief Accounting Officer
- Shares
- 1,359
- Price
- $69.20
- Value
- $94,046
- Cho DennisSale
29 May 2026, See Remarks
- Shares
- 14,205
- Price
- $69.75
- Value
- $990,799
- Laponis AdamSale
29 May 2026, Chief Financial Officer
- Shares
- 4,000
- Price
- $70.00
- Value
- $280,000
- Leproust Emily M.Sale
28 May 2026, Chief Executive Officer
- Shares
- 16,470
- Price
- $67.91
- Value
- $1.12M
- Starovasnik Melissa A.Sale
28 May 2026, Board
- Shares
- 2,500
- Price
- $68.00
- Value
- $170,000
- Leproust Emily M.Sale
27 May 2026, Chief Executive Officer
- Shares
- 25,017
- Price
- $65.29
- Value
- $1.63M
- Starovasnik Melissa A.Sale
26 May 2026, Board
- Shares
- 500
- Price
- $61.04
- Value
- $30,520
- Leproust Emily M.Sale
26 May 2026, Chief Executive Officer
- Shares
- 24,282
- Price
- $65.08
- Value
- $1.58M
- Werner Robert F.Sale
26 May 2026, Chief Accounting Officer
- Shares
- 800
- Price
- $62.48
- Value
- $49,987
- Green PaulaSale
21 May 2026, SVP of Human Resources
- Shares
- 1,399
- Price
- $53.26
- Value
- $74,507
- Finn Patrick JohnSale
21 May 2026, President and COO
- Shares
- 4,160
- Price
- $53.26
- Value
- $221,549
- Cho DennisSale
21 May 2026, See Remarks
- Shares
- 1,642
- Price
- $53.26
- Value
- $87,448
- Werner Robert F.Sale
21 May 2026, Chief Accounting Officer
- Shares
- 688
- Price
- $53.26
- Value
- $36,641
- Leproust Emily M.Sale
21 May 2026, Chief Executive Officer
- Shares
- 6,888
- Price
- $53.26
- Value
- $366,834
- Laponis AdamSale
21 May 2026, Chief Financial Officer
- Shares
- 2,019
- Price
- $53.26
- Value
- $107,526
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Twist Bioscience
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- CytokineticsCYTK $7.82B33
- 10x GenomicsTXG $7.73B43
- Rhythm PharmaceuticalsRYTM $7.62B41
- Axsome TherapeuticsAXSM $7.59B31
- ImmunovantIMVT $7.25B45
- Bachem HoldingBANB.SW $7.25B58
- Caris Life SciencesCAI $6.87B57
- Kodiak SciencesKOD $6.8B43
ETFs that hold Twist Bioscience
Held by 17 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 6.48% | 0.68% | €5.31M |
| Global X Genomics & Biotechnology UCITS ETFGN0M | 5.54% | 0.50% | €127.64M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 2.03% | 0.49% | €318.64M |
Show 5 more
| iShares Healthcare Innovation UCITS ETF2B78 | 0.68% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.53% | 0.35% | €1.25B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.43% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.30% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.30% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- Valuation signal Fairly valued since 13 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.